NavinRobertPintoMD

Pediatric Hematology & Oncology • Seattle, WA

Pediatric Solid Tumor Oncology

Associate Professor of Pediatrics

Join to view full profile

Dr. Pinto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pinto's full profile

Already have an account?

Office
4800 Sand Point Way NE
Seattle, WA 98105

Education & Training

University of ChicagoFellowship, Pediatric Hematology/Oncology, 2008 - 2011
University of ChicagoResidency, Pediatrics, 2005 - 2008
Saint Louis University School of MedicineClass of 2005

Certifications & Licensure

CO State Medical License 2023 - 2025
WA State Medical License 2015 - 2024
ID State Medical License 2021 - 2023
IL State Medical License 2005 - 2017
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Start of enrollment: 2012 Aug 01
Completed
Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Start of enrollment: 2019 Sep 27
Active, not recruiting
Phase 1
Roles: Contact
Neuroblastoma Biology Study Start of enrollment: 2011 Jul 01
Recruiting
Roles: Contact
Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE Start of enrollment: 2021 Aug 28
Active, not recruiting
Roles: Contact
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1
Roles: Contact
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study Start of enrollment: 2015 Oct 01
Active, not recruiting
Roles: Contact
MIBG With Dinutuximab +/- Vorinostat Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 1
Roles: Contact
9-ING-41 in Pediatric Patients With Refractory Malignancies. Start of enrollment: 2020 Jun 05
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

37 citations
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi
Nature Medicine. 2023-05-01
3 citations
Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A...
Navin Pinto, Arlene Naranjo, Xiangming Ding, Fan F Zhang, Emily Hibbitts
Clinical Cancer Research. 2023-04-14
8 citations
Clinical Targeted Next-Generation Panel Sequencing RevealsAmplification Is a Poor Prognostic Factor in Osteosarcoma.
Amanda E Marinoff, Liam F Spurr, Christina Fong, Yvonne Y Li, Suzanne J Forrest
JCO Precision Oncology. 2023-03-01

Press Mentions

HAPPENING NOW: Life-Saving Dodgeball @ RiverviewSeptember 25th, 2021
Pediatric Cancer in Yakima Valley: 'Sometimes You Want to Collapse, but You Can't'October 6th, 2019